Hedge Fund Stock Picks & Ticker Coverage
Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Letter Commentary & Co-Mentions | Period / Date | Action |
|---|---|---|---|
“Baird's small/mid-cap growth strategy underperformed in Q3 as GLP-1 drug developments hammered medical device holdings and rising rates pressured consumer names. The team added...” | Q3 2023 Sep 30, 2023 | Preview | |
“Baird's small/mid-cap growth strategy underperformed in Q2 as their bias toward profitable, higher-multiple stocks faced headwinds. Consumer discretionary led...” | Q2 2023 Jun 30, 2023 | Preview |
Read unredacted commentary excerpts, portfolio weight disclosures, and high-conviction theses from hedge fund managers discussing $CNMD.(1 additional institutional mentions locked).
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.